Market Overview:
Antisense oligonucleotides are short DNA or modified RNA sequences that are used to alter or inhibit the expression of specific genes. They are mainly used in research and therapeutics of genetic disorders such as Huntington's disease and Duchenne muscular dystrophy. They work by selectively binding to messenger RNA (mRNA) or microRNA (miRNA) through the mechanism of sequence-specific hybridization. This blocks the translation of specific mRNAs and prevents the synthesis of targeted proteins.
Market Dynamics:
The antisense oligonucleotides market is expected to witness significant growth over the forecast period owing to rising prevalence of genetic disorders across the globe. For instance, according to the Global Genes organization, around 7,000 rare diseases have been identified, out of which around 80% have a genetic origin. Moreover, increasing research activities in fields of gene silencing and translation inhibition using antisense oligonucleotides is also expected to boost the market growth.
Significant investments made in the research and development of antisense therapeutics is another key factor driving the antisense oligonucleotides market over the forecast period. Large number of antisense oligonucleotides currently under clinical trial indicates the presence of robust product pipeline which is anticipated to expand the market size. Furthermore, regenerative capabilities shown by oligonucleotides make them an attractive therapeutic agent for various incurable health conditions like spinal muscular atrophy and neurological disorders.
The global Antisense Oligonucleotides Market Share is estimated to be valued at US$ 2,913.5 Mn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis
Strength: the antisense oligonucleotide therapeutics have high specificity for the targets. They can selectively block the expression of disease-causing genes at the RNA level with minimal off-target effects. The mechanism of action is well characterized and they have demonstrated clinical efficacy in various disease conditions.
Weakness: developing antisense oligonucleotides is an expensive endeavor requiring substantial R&D investments. The delivery and functionality of antisense oligonucleotides in the body also present challenges.
Opportunity: the increasing focus on precision medicine for treating various genetic disorders present a major market opportunity for antisense oligonucleotides. The rising cases of neurological disorders also offer growth prospects.
Threats: the regulatory requirements for approval are stringent. Failures in clinical trials pose risks. Competitive threats from other novel drug modalities also exist.
Key Takeaways
The global antisense oligonucleotides market is expected to witness high growth, exhibiting CAGR of 6.6% over the forecast period, due to increasing focus on precision medicine for treating genetic disorders.
Market size: The antisense oligonucleotides market size for 2023 is US$ 2,913.5 Mn. The market is estimated to grow substantially due to rising application of antisense drugs in neurological disorders like spinal muscular atrophy (SMA).
Regional analysis: North America dominates the global antisense oligonucleotides market currently. This is attributed to strong diagnostic infrastructure, higher awareness about precision medicine, and frequent approvals for antisense drugs in the region. Asia Pacific is expected to emerge as the fastest growing regional market over the forecast period, fueled by expanding healthcare industry and investments in pharmaceutical R&D.
Key players: Key players operating in the antisense oligonucleotides market are Antisense Therapeutics, Biogen, Bio-Path Holdings, Ionis Pharmaceuticals, ProQR Therapeutics, Sarepta Therapeutics, Sterna Biologicals and Wave Life Sciences. Ionis Pharmaceuticals and Biogen currently lead the market with several approved drugs and candidates in clinical trials.
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian